Clinical trial
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With…
NCT00058747 · Agenus Inc., Industry · Terminated
Key facts
| NCT number | NCT00058747 |
|---|---|
| Title | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ |
| Official title | Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™ |
| Lead sponsor | Agenus Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Drug |
| Interventions | Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™. |
| Enrollment | 40 |
| Start date | Mar 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Apr 15, 2003 |
| Last update posted | Sep 7, 2012 |
| Countries | United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: